The latest news & stories from the Providence Research Network

Learn how Providence is bringing top-tier research to its rural health programs so patients have access to lifesaving therapies – wherever they are.

A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.

Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.

SITC 2023 provides a glimpse into scientific advances and breakthroughs in cancer immunotherapy by researchers from around the world.

A new study examined patient experiences with long-COVID and identified four distinct groupings encompassing the wide-ranging experiences of long COVID patients.

The OakTree study is looking at a new COVID-19 drug to see if it can shorten the time you have symptoms. Learn more about participating.

Swedish Edmonds Dr. Kelly Paulson wins the first-ever Jeff Ward Award for excellence in care.

Jaundice was the first symptom of what a CT scan would confirm was pancreatic cancer. A small tumor blocked one of Sharon Stefan’s bile ducts, causing the telltale symptom that, for many, doesn’t appe

Providence study seeks to help practitioners better identify and care for patients by providing a more comprehensive understanding of how long COVID presents and the patient experience of this disease

Two new studies available at Earle A. Chiles Research Institute, at division of Providence Cancer Institute of Oregon, to evaluate new treatments for triple-negative breast cancer.

A recent study found an increased prevalence of cancer in people under 50. The study noted increases of endocrine, gastrointestinal and breast cancers in people between the ages of 30 and 39.

Providence Cancer Institute of Oregon, and research director, Earle A. Chiles Research Institute, Walter J. Urba, M.D., Ph.D., receives award for his contributions to science and community.

The METH-OD Study works to reverse the effects of Methamphetamine abuse. Read more about this innovative research and its successful outcomes for patients.

Providence Swedish is at the forefront of new technologies that decrease pain and shorten recovery time for prostate cancer patients.

Providence Cancer Institute of Oregon announces new division director and deputy director of Hematology and Medical Oncology.

For Gynecologic Cancer Awareness Month, Providence Cancer Institute highlights a clinical trial that evaluates the safety and effectiveness of a new oral treatment for grade 1 endometrial cancer.

A global study co-authored by Providence researchers shows significant promise for the treatment of Chronic lymphocytic leukemia/Small Lymphocytic Lymphoma

A new study by Providence CORE linked a Value-based Payment Model with increased use of primary and specialty care among patients. Findings also highlight the importance of clinical staff buy-in.

New trial open at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, is enrolling patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.